example alt text

Financial Reports

 

Interim 2008Annual Report 2010

  • Variquel (Haemopressin) launched in 13 European markets with revenues up 80%
  • Aloxi revenues up 84% and now recommended in key
    international cancer guidelines
  • Acquisition of the exclusive European rights for oncology
    supportive care product, Episil
  • Acquisition of exclusive UK rights for the oncology
    supportive care product, aquoral® (Aequasyal) with
    an option for Germany
  • Distribution and Sale Agreement for Volplex® and Isoplex® for total consideration of up to £1.4m

 

 

 

Interim 2009

Interim Report 2009

  • Revenue £5.9m (H1 2008: £5.8m) underlying revenues up 16% (H1 2008: £5.1m)*
  • Gross Profit £3.7m (H1 2008: £3.8m) underlying gross profit up 17% (H1 2008: £3.1m)*
  • Cash Balance £4.2m (H1 2008: £2.2m) (net cash £0.8m
    (2008: £2.2m))

 

 

 

Previous Reports

Annual Reports

Interim Reports
Annual Report 2009 Interim Report 2008
Annual Report 2008 Interim Report 2007
Annual Report 2007 Interim Report 2006
Annual Report 2006 Interim Report 2005
Annual Report 2005 Interim Report 2004
Annual Report 2004 Interim Report 2003
Annual Report 2003 Interim Report 2002
Annual Report 2002 Interim Report 2001
Annual Report 2001 Interim Report 2000
Annual Report 2000  

 

Financial Calendar

Year end – 31 March 2010
Prelim results – announced 2 June 2010
AGM – 27 July 2010
Interim results – November 2010 (to be confirmed)